TLDR PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
The document discussed the PRIDE syndrome, which was a practical way to identify adverse skin effects associated with the use of epidermal growth factor receptor (EGFR) inhibitors, such as erlotinib. These dermatological side effects included pruritic papulopustular eruptions, xerosis, paronychia, and non-scarring diffuse alopecia. These conditions could be bothersome and disabling, but timely intervention improved patients' quality of life and adherence to treatment. The document presented a case of a patient who developed these symptoms after starting treatment with erlotinib.
90 citations
,
August 2006 in “British Journal of Dermatology” PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
192 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause serious skin problems that need careful management.
26 citations
,
February 2015 in “Pediatric blood & cancer” Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
278 citations
,
May 2013 in “Ca” Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
26 citations
,
October 2018 in “Clinical & Translational Oncology” Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
32 citations
,
January 2012 in “International Journal of Dermatology” Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
